Jump to content

Rick

Members
  • Content Count

    70
  • Joined

  • Last visited

  • Days Won

    18

Rick last won the day on July 5

Rick had the most liked content!

Community Reputation

35 Excellent

2 Followers

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

  1. Things are continuing to go well for us here at Kimer Med. We are excited to announce that we have signed an exclusive license agreement for US patent 7566694, “Anti-Pathogen Treatments,” which is the one and only remaining active patent related to Todd Rider’s original DRACO work. This gives us an excellent IP foundation for work with our compound in the United States. Our fabrication and testing continues. The end-to-end process takes multiple months. Much of our current testing and analysis is focused on characterizing the chemical aspects of our compound and how it behaves during
  2. Rick

    New office

    We recently leased an office here in Nelson, New Zealand. Finding a good space was a bit of an ordeal, but it's done, and we're all moved-in now, and getting comfortable. Here are a couple of photos of the new space, in case you're curious.
  3. The short answer is ... maybe. There are some interesting connections and cross-over points between viruses and cancer, and it's definitely something we're thinking about. However, there's nothing concrete or proven or even in the current experiment pipeline -- so, as you said, "probably far far away." As to whether viruses may be able to "build immunity" to VTose® somehow: we don't know. Based on the mechanism of action, about all I can say is that it might be possible; viruses are wily little critters, and evolution is a remarkably powerful thing. However, based on its mechanism of acti
  4. Rick

    Rabies treatment

    Rabies is certainly one of the viruses we're interested in, largely due to the issue you pointed out: without treatment, it's nearly always fatal. We don't know yet whether VTose® is effective against the virus. Regarding whether neurological damage would happen as a result of treatment, it's much too soon to say. Even if it is effective, many other factors are involved, including things like how far the infection has progressed, which cell types are infected, method and timing of drug administration, and so on.
  5. Things have been going well for us at Kimer Med. Here's the latest: Dengue Fever is a tropical viral disease that infects up to 400 million people every year in parts of Africa, Southeast Asia and Central and South America. According to the CDC, it lacks effective treatments, resulting in about 100 million people developing symptomatic disease and 22,000 deaths from those infections every year. Dengue is transmitted by mosquitos. Getting infected a second time is much more risky than the first time. Dengue is also interesting to us since it has some features in common with SARS-CoV-2
  6. Hi , Greetings from New Zealand! I hope you're doing well. Since my last email about our biotech startup, Kimer Med, we've made tremendous progress. I thought you might be interested in hearing our most recent news: we successfully closed our seed funding round. This will enable us to greatly expand the scope and speed of development of our broad-spectrum antiviral drug. If you're interested in following our work on a regular basis, you can sign-up for our subscriber email list here: https://kimermed.co.nz/landing We also have a discussion forum: https://forum.kimermed.
  7. Very interesting! Thanks for the link.
  8. Greetings from Kimer Med. We've had a productive week on the science front, including completing four different types of analysis of our antiviral protein, and a fifth is in progress. The results of these tests will be used to help inform our ongoing efforts to improve the fabrication process and product purity. We are currently using E. Coli bacteria to make the protein, although it's possible that will change at some point. Recombinant protein fabrication is a fascinating field! Our fundraising efforts continue. If you'd like to support our work and help us move faster, here's
  9. Greetings from Kimer Med! Our fundraising and science efforts are continuing apace. Nothing new to report at the moment, but I thought I'd send a quick update anyway, to let you know that things are still moving forward. Operating on a shoestring, as we are at the moment, definitely slows us down. If you'd like to support our work and help us move faster, we have a new donation page on our website: https://www.kimermed.co.nz/donate Covid-related news has been interesting lately. Between reports of new strains and vaccine failures of various kinds, it's clear t
  10. Hi, I hope you had a good holiday and a happy new year. Just a short update this week, since as I mentioned last time, New Zealand pretty much closes down from mid-Dec to mid-Jan for the holidays. Things will finally be coming back to life next week. On the science side, the protein from the second fabrication batch that I mentioned in my last update is now in-hand. As the last step of fabrication, we run the dissolved compound through a 0.2 micron filter, which effectively sterilizes it. After that, it can be safely stored at 4C (in a standard refrigerator). The
  11. Hi, Our crowdfunding campaign is now complete. We raised NZ $24,200 (about USD $17,000). Thanks again to those who donated! We have recently completed fabrication of the second batch of our protein, with significantly improved purity and yield. Excellent progress. We are now working on replicating some of the basic antiviral functionality described in the 2011 paper about DRACO. There is a surprising amount of interesting and complex science involved. We are anticipating that several iterations of fabrication and testing may be required. In case you haven't b
  12. Hi, Our crowdfunding campaign is coming down to its last 48 hours. Thanks if you have already donated. In case you haven't had a chance to check out the campaign recently, here's a link: https://donate.kimermed.co.nz/campaign/2/ending-viral-disease Since the last Weekly Update, there have been a couple of new posts in the members only section of the forum: https://forum.kimermed.co.nz/index.php?/forum/15-general-discussion/ If you made a donation more than about a week ago and don't yet have access to that part of the forum, please let me know (more recent
  13. Rick

    Delivery method

    The molecular weight of VTose is roughly 35 kDa. One of the earliest papers about transduction tags showed effectiveness with a protein with a MW of 120 kDa: In vivo protein transduction: delivery of a biologically active protein into the mouse - PubMed (nih.gov) Transport of even larger proteins is undoubtedly possible.
  14. Specific treatment protocols is one of the things we will be researching. We certainly will also be putting some effort into trying to develop an oral form. However, proteins are very susceptible to damage and degradation by the digestive system, so it's a challenge. Insulin, for example, which is a relatively small peptide (a short protein), still doesn't have an oral form.
  15. For Rider's study with mice to treat Influenza, he only treated them for a few days. Dosing in humans will depend on a number of factors, such as the type of virus being treated, the severity of the infection, whether there are other viral co-infections, and so on. We are also looking at formulation changes that are intended to influence the required dose. The specifics in this area are one of the many things that we plan to determine during clinical trials.
×
×
  • Create New...